Immunome Inc.(IMNM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMNM Immunome Inc.

Closed 04-03 16:00:00 EDT

6.24

-0.47

-7.00%

盘后6.23

-0.01-0.16%

19:43 EDT

High6.55	Low6.08	Vol1.13M
Open6.26	D1 Closing6.71	Amplitude6.90%
Mkt Cap542.57M	Tradable Cap420.51M	Total Shares86.95M
T/O7.04M	T/O Rate1.67%	Tradable Shares67.39M
P/B2.99	ROE-194.63%	EPS-5.69
52wk High22.03	52wk Low6.08	P/E-1.10
Dividend0.00	Div.Yield0.00	ROA-49.34%

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"IMNM","market":"US","secType":"STK","nameCN":"Immunome Inc.","latestPrice":6.24,"timestamp":1743710400000,"preClose":6.71,"halted":0,"volume":1125356,"hourTrading":{"tag":"盘后","latestPrice":6.23,"preClose":6.24,"latestTime":"19:43 EDT","volume":16361,"amount":102214.94,"timestamp":1743723830889},"delay":0,"floatShares":67389800,"shares":86950700,"eps":-5.693849,"marketStatus":"Closed","change":-0.47,"latestTime":"04-03 16:00:00 EDT","open":6.26,"high":6.5457,"low":6.0827,"amount":7041825.704198,"amplitude":0.069001,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-5.693849,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743753600000},"marketStatusCode":5,"adr":0,"listingDate":1601611200000,"exchange":"NASDAQ","adjPreClose":6.71,"preHourTrading":{"tag":"盘前","latestPrice":6.26,"preClose":6.71,"latestTime":"09:29 EDT","volume":1333,"amount":8428.1902922,"timestamp":1743686999999},"postHourTrading":{"tag":"盘后","latestPrice":6.23,"preClose":6.24,"latestTime":"19:43 EDT","volume":16361,"amount":102214.94,"timestamp":1743723830889},"volumeRatio":0.507538,"impliedVol":1.4244,"impliedVolPercentile":0.9402},"requestUrl":"/m/hq/s/IMNM","defaultTab":"news","newsList":[{"id":"2524219610","title":"Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2524219610","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524219610?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 05:07","pubTimestamp":1743714470,"startTime":"0","endTime":"0","summary":"April 3 (Reuters) - Immunome Inc ::*IMMUNOME REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 03-APR-202520:05:00.563 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250403:nRSDbWJTCk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNM","BK4139","BK4563"],"gpt_icon":0},{"id":"2524605467","title":"Immunome initiated with a Buy at Lake Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2524605467","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524605467?lang=en_us&edition=full_marsco","pubTime":"2025-04-02 19:50","pubTimestamp":1743594614,"startTime":"0","endTime":"0","summary":"Lake Street analyst Chad Messer initiated coverage of Immunome (IMNM) with a Buy rating and $23 price target The company’s lead clinical program, v...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunome-initiated-with-a-buy-at-lake-street?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunome-initiated-with-a-buy-at-lake-street?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4563","IMNM"],"gpt_icon":0},{"id":"2523171969","title":"Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2523171969","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523171969?lang=en_us&edition=full_marsco","pubTime":"2025-03-31 19:00","pubTimestamp":1743418800,"startTime":"0","endTime":"0","summary":"– FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET clinical development program since ACR C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/31/3052139/0/en/Cabaletta-Bio-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ1G4Q59.USD","BK4534","LU2347655156.SGD","LU0320765646.SGD","LU2023251221.USD","LU2133065610.SGD","LU2089283258.USD","LU0106831901.USD","LU1732800096.USD","LU0098860793.USD","CDMO","LU0158827948.USD","LU0795875169.SGD","CABA","LU0106261372.USD","SLE","IMNM","LU0006306889.USD","LU0314104364.USD","LU0225283273.USD","LU0912757837.SGD","LU2111349929.HKD","LU2271345857.HKD","BK4077","BK4563","LU0267386448.USD","LU0971096721.USD","LU1074936037.SGD","LU1363072403.SGD","LU1720051108.HKD","LU1989772840.SGD","LU1720051017.SGD","LU2028103732.USD","BK4504","BK4127","BK4581","LU1989772923.USD","LU1732799900.SGD","LU2357305700.SGD","IE00BKVL7J92.USD","LU1668664300.SGD","BK4516","LU0158827781.USD","LU2089284900.SGD","BK4588","BK4139","BK4585","LU0795875086.SGD","LU1162221912.USD","LU1548497426.USD"],"gpt_icon":0},{"id":"2522988883","title":"Immunome Executives Make Bold Moves with Major Stock Purchases!","url":"https://stock-news.laohu8.com/highlight/detail?id=2522988883","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522988883?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 10:02","pubTimestamp":1743040923,"startTime":"0","endTime":"0","summary":"New insider activity at Immunome ( ($IMNM) ) has taken place on March 27, 2025. In a significant move, Immunome’s Director Jean Jacques Bienaime ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/immunome-executives-make-bold-moves-with-major-stock-purchases?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/immunome-executives-make-bold-moves-with-major-stock-purchases?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMNM","BK4139","BK4563"],"gpt_icon":0},{"id":"2522536369","title":"Closing Bell Movers: GameStop gains 7% on earnings, bitcoin announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2522536369","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522536369?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 08:00","pubTimestamp":1743033622,"startTime":"0","endTime":"0","summary":"In the opening 90 minutes of the evening session, U.S. stock futures are up marginally – S&P500 is up 0.1% while Nasdaq 100 is up 0.2%. Earlier on Tuesday, Consumer Discretionary and Communications Services were the best performing sectors in the S&P500 – Google , Meta , and Netflix  had over 1% gains among the mega-caps – while defensively-oriented Healthcare and Utilities underperformed.  Investors have also shrugged the disappointing Consumer Confidence data with sentiment turning more upbeat on expectations of a more tempered tariff implementation by the White House and translating into 3rd consecutive session of gains.Discover stocks' market position with detailed  competitor analyses.In Commodities, WTI Crude Oil contract remains bid above the $69 per barrel handle. After two consecutive weeks of large builds, API Petroleum inventories data saw its largest weekly draw of 2025, signifying increase in demand.Check out this evening’s top movers from around Wall Street, compiled by T","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/closing-bell-movers-gamestop-gains-000022309.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/closing-bell-movers-gamestop-gains-000022309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GOOGL","NFLX","GME","KGEI","GOOG","PAYS","SURG","IMNM","SURGW","META"],"gpt_icon":1},{"id":"1188791227","title":"Stock Track | Immunome Inc. Surges 6.19% in Pre-market Following CTO's $103,600 Insider Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1188791227","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188791227?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 19:14","pubTimestamp":1742987693,"startTime":"0","endTime":"0","summary":"Immunome Inc.  stock continued its upward trajectory, soaring 6.19% in pre-market trading on Wednesday. This surge follows an already impressive 6.33% gain observed in the previous trading session, as investors react positively to a significant insider purchase by the company's Chief Technology Officer .According to a recent regulatory filing, Immunome's CTO Philip Tsai acquired 12,300 shares of common stock on March 24th, with the transaction totaling approximately $103,600. This substantial in","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["IMNM"],"gpt_icon":0},{"id":"1137889825","title":"Stock Track | Immunome Stock Soars 6.33% Following CTO's $103.6K Insider Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1137889825","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137889825?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 11:32","pubTimestamp":1742959958,"startTime":"0","endTime":"0","summary":"Immunome Inc.  shares experienced a significant surge, soaring 6.33% in a 24-hour period ending Tuesday evening. This remarkable uptick in stock price appears to be directly linked to a notable insider purchase by the company's Chief Technology Officer .According to a regulatory filing, Immunome's CTO Philip Tsai acquired 12,300 shares of common stock on March 24th, with the total transaction amounting to approximately $103,600. This substantial investment by a key executive has been interpreted","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["IMNM"],"gpt_icon":0},{"id":"1138793375","title":"Stock Track | Immunome Stock Soars 6.33% Following CTO's $103,600 Insider Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1138793375","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138793375?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 11:32","pubTimestamp":1742959950,"startTime":"0","endTime":"0","summary":"Immunome Inc.  shares experienced a significant surge, soaring 6.33% in a 24-hour period, following news of a substantial insider purchase by the company's Chief Technology Officer . The stock's impressive performance comes as investors react positively to the show of confidence from a key executive.According to a regulatory filing, Immunome's CTO Philip Tsai acquired 12,300 shares of common stock on March 24th, with the total transaction amounting to approximately $103,600. This insider buying ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["IMNM"],"gpt_icon":0},{"id":"1115041765","title":"Stock Track | Immunome Surges 6.04% After Hours Following CTO's $103.6K Stock Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1115041765","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115041765?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 05:46","pubTimestamp":1742939192,"startTime":"0","endTime":"0","summary":"Immunome Inc.  shares soared 6.04% in after-hours trading on Tuesday, following news of a significant insider purchase by the company's Chief Technology Officer .According to a regulatory filing, Immunome's CTO Philip Tsai acquired 12,300 shares of common stock on March 24th. The total transaction amounted to approximately $103,600, signaling a strong vote of confidence in the company's future prospects from a key executive.Insider buying, particularly by high-ranking officers such as the CTO, i","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["IMNM"],"gpt_icon":0},{"id":"1186015772","title":"Stock Track | Immunome Surges 6.04% After-Hours Following CTO's $103.6K Stock Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=1186015772","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186015772?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 05:46","pubTimestamp":1742939191,"startTime":"0","endTime":"0","summary":"Immunome Inc.  shares soared 6.04% in after-hours trading on Tuesday, following a significant insider purchase disclosed in a regulatory filing. The biotechnology company's stock price movement comes on the heels of its Chief Technology Officer's decision to acquire a substantial amount of company shares.According to the filing, Immunome's CTO Philip Tsai bought 12,300 shares of common stock on March 24th, representing a total transaction value of approximately $103,600. This insider buying acti","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Immunome Surges 6.04% After-Hours Following CTO's $103.6K Stock Purchase","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["IMNM"],"gpt_icon":0},{"id":"2522836459","title":"Immunome CTO buys $103.6K in common stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2522836459","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522836459?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 05:30","pubTimestamp":1742938212,"startTime":"0","endTime":"0","summary":"In a regulatory filing, Immunome (IMNM) disclosed that its CTO Philip Tsai bought 12.3K shares of common stock on March 24th in a total transaction...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunome-cto-buys-103-6k-in-common-stock?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunome-cto-buys-103-6k-in-common-stock?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4563","IMNM","CTO","BK4160","BK4139"],"gpt_icon":0},{"id":"2522503521","title":"Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Sanofi (OtherSNYNF) and MacroGenics (MGNX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522503521","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522503521?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 08:50","pubTimestamp":1742863809,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Immunome (IMNM – Research Report), Sanofi (SNYNF – R...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-immunome-imnm-sanofi-othersnynf-and-macrogenics-mgnx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-immunome-imnm-sanofi-othersnynf-and-macrogenics-mgnx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4137","SNYNF","BK4007","IMNM","MGNX","BK4139","BK4563"],"gpt_icon":0},{"id":"1108501127","title":"Stock Track | Immunome Plummets 5.08% After Reporting Wider Losses and Missed Estimates for FY 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=1108501127","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108501127?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 03:30","pubTimestamp":1742585434,"startTime":"0","endTime":"0","summary":"Shares of Immunome Inc.  plunged 5.08% in Friday's trading session following the release of the company's disappointing Full Year 2024 financial results. The biotechnology firm reported a significant widening of its net loss and missed analyst expectations on both revenue and earnings.According to the earnings report, Immunome's net loss for the fiscal year 2024 expanded to $293.0 million, representing a substantial 174% increase from the previous year. The company reported a loss per share of $","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["IMNM"],"gpt_icon":0},{"id":"1151296645","title":"Stock Track | Immunome Plummets 5.08% Following Disappointing 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1151296645","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151296645?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 03:30","pubTimestamp":1742585422,"startTime":"0","endTime":"0","summary":"Immunome Inc.  saw its stock price plummet by 5.08% in Friday's trading session following the release of its full-year 2024 financial results. The biotechnology company reported a significant widening of its net loss and missed analyst expectations, raising concerns among investors about its financial performance and future prospects.The company reported a net loss of $293.0 million for the full year 2024, representing a substantial 174% increase from the previous year. This translated to a loss","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | Immunome Plummets 5.08% Following Disappointing 2024 Financial Results","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["IMNM"],"gpt_icon":0},{"id":"2521037934","title":"North American Morning Briefing: Stock Futures Fall as Focus Shifts From Fed to Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2521037934","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521037934?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 18:02","pubTimestamp":1742551320,"startTime":"0","endTime":"0","summary":"The euphoria from the Federal Reserve's policy meeting didn't last long.Stock futures were lower Friday as attention shifted from the Fed to the prospect of further tariffs.Trump said in a social media post that the planned imposition of reciprocal tariffs on April 2 would be \"Liberation Day\" in the U.S.\"We maintain our view that the FOMC outcome was effectively a one-day move, with minimal legacy in terms of immediate direction. That said, we also view the FOMC outcome as a whole as nodding towards dovishness, but with numerous caveats,\" ING said.Quantum-computing stocks  are likely to be in focus after suffering steep falls on Thursday as investors appeared unimpressed by their contributions to Nvidia's Quantum Day at its GTC developers' event.The market also faces a test as an estimated $4.5 trillion in options contracts expire, which could increase volatility.FedEx fell 5.1% off hours after it cut its outlook for the year.Lennar management warned investors of a weak housing market.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BPTH","NVDA","SMXT","XOMA","DM","IRD","NGNE","NVDS","ZBIO","CKPT","NVD2.UK","PURE","US10Y.BOND","AFG","NVDL","SNVD.UK","NVDD","ATXI","FBLG","NVDX","US7Y.BOND","GORV","IMNM","DXYN","NVIW.SI","IMRX","USAU","MPU","NVDY","PRPH","SGMA","US3Y.BOND","NVDU","JVA","2NVD.UK","OLMA","NVDS.UK","US12M.BOND","NVD3.UK","ET","CCL","US5Y.BOND","US2Y.BOND","ADVM","US30Y.BOND","US6M.BOND","3NVD.UK","BOLD","FBRX"],"gpt_icon":1},{"id":"2521444235","title":"Immunome’s 2024 Financial Results and Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2521444235","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521444235?lang=en_us&edition=full_marsco","pubTime":"2025-03-21 12:06","pubTimestamp":1742529992,"startTime":"0","endTime":"0","summary":"Immunome, Inc. ( ($IMNM) ) has released its Q4 earnings. Here is a breakdown of the information Immunome, Inc. presented to its investors. Immunome...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/immunomes-2024-financial-results-and-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/immunomes-2024-financial-results-and-pipeline-progress?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4563","LU2065732104.USD","BK4139","PRGS","BK4097","IMNM"],"gpt_icon":0},{"id":"2520452316","title":"Immunome Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2520452316","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520452316?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 21:41","pubTimestamp":1742478060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMNM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2025 09:41 ET (13:41 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMNM"],"gpt_icon":0},{"id":"2520453908","title":"Immunome price target lowered to $25 from $35 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2520453908","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520453908?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 19:51","pubTimestamp":1742471479,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Michael Schmidt lowered the firm’s price target on Immunome (IMNM) to $25 from $35 and keeps a Buy rating on the shares after up...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunome-price-target-lowered-to-25-from-35-at-guggenheim?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunome-price-target-lowered-to-25-from-35-at-guggenheim?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMNM"],"gpt_icon":0},{"id":"2520434742","title":"Immunome (IMNM) Receives a Buy from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2520434742","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520434742?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 18:38","pubTimestamp":1742467101,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Biren Amin maintained a Buy rating on Immunome (IMNM – Research Report) today and set a price target of $21.00. The company’s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/immunome-imnm-receives-a-buy-from-piper-sandler?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/immunome-imnm-receives-a-buy-from-piper-sandler?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IMNM","BK4563"],"gpt_icon":0},{"id":"2520586191","title":"Immunome 2024 Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2520586191","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520586191?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 05:06","pubTimestamp":1742418390,"startTime":"0","endTime":"0","summary":"Immunome  reported a 2024 net loss Wednesday of $5 per diluted share, narrowing from the loss of $5.38 a year earlier.Analysts polled by FactSet expected a loss of $4.38.Collaboration revenue fell to $9.04 million from $14 million a year earlier.Analysts surveyed by FactSet expected $9.4 million.As of Dec. 31, the company had cash, cash equivalents and marketable securities of $217.3 million, excluding gross proceeds of $172.5 million from financing in January, the company said. The current cash runway is expected to extend into 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4563","BK4139","IMNM"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunome.com","stockEarnings":[{"period":"1week","weight":-0.0536},{"period":"1month","weight":-0.2494},{"period":"3month","weight":-0.3628},{"period":"6month","weight":-0.4905},{"period":"1year","weight":-0.6863},{"period":"ytd","weight":-0.3682}],"compareEarnings":[{"period":"1week","weight":-0.0072},{"period":"1month","weight":-0.033},{"period":"3month","weight":-0.0344},{"period":"6month","weight":-0.0148},{"period":"1year","weight":0.088},{"period":"ytd","weight":-0.0368}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01 that targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.8,"avgChangeRate":0.434652},{"month":2,"riseRate":0.4,"avgChangeRate":0.326996},{"month":3,"riseRate":0.4,"avgChangeRate":-0.090619},{"month":4,"riseRate":0,"avgChangeRate":-0.205489},{"month":5,"riseRate":0.75,"avgChangeRate":-0.00531},{"month":6,"riseRate":0.25,"avgChangeRate":-0.0071},{"month":7,"riseRate":0.5,"avgChangeRate":0.081647},{"month":8,"riseRate":0.25,"avgChangeRate":0.057093},{"month":9,"riseRate":0.5,"avgChangeRate":0.191692},{"month":10,"riseRate":0.25,"avgChangeRate":-0.054239},{"month":11,"riseRate":0.2,"avgChangeRate":-0.036745},{"month":12,"riseRate":0.2,"avgChangeRate":-0.144549}],"exchange":"NASDAQ","name":"Immunome Inc.","nameEN":"Immunome Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunome Inc.(IMNM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immunome Inc.(IMNM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immunome Inc.,IMNM,Immunome Inc.股票,Immunome Inc.股票老虎,Immunome Inc.股票老虎国际,Immunome Inc.行情,Immunome Inc.股票行情,Immunome Inc.股价,Immunome Inc.股市,Immunome Inc.股票价格,Immunome Inc.股票交易,Immunome Inc.股票购买,Immunome Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunome Inc.(IMNM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immunome Inc.(IMNM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction